Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 1;21(4):409-421.
doi: 10.17305/bjbms.2020.5485.

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

Jiale Ma  1 , Zheng Ge  2
Affiliations
Review

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia

Jiale Ma et al. Bosn J Basic Med Sci. .

Abstract

Despite advances in the understanding of disease pathobiology, treatment for relapsed or refractory acute myeloid leukemia (R/R AML) remains challenging. The prognosis of R/R AML remains extremely poor despite chemotherapy and bone marrow transplants. Discoveries on recurrent and novel genetic mutations, such as FLT3-ITD and IDH1/IDH2, critical signaling pathways, and unique molecular markers expressed on the surface of leukemic cells have been under investigation for the management of R/R AML. Other than monoclonal antibodies, diabodies, and triabodies are new targeted therapies developed in recent years and will be the new direction of immunotherapy. Targeted agents combined intensive regimens can be viable options for salvage therapy and as bridges to allogeneic transplant. Future directions will focus on novel, efficient and targeted combinations, low-toxicity maintenance, and individualized precision strategies. Here, we review the major recent advances of targeted therapies in the treatment of R/R AML.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21. - PMC - PubMed
    1. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients:The ECOG-ACRIN experience. Am J Hematol. 2018;2018:25162. https://doi.org/10.1002/ajh.25162. - PMC - PubMed
    1. Bergua JM, Montesinos P, Martinez-Cuadron D, Fernandez-Abellan P, Serrano J, Sayas MJ, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174(5):700–10. https://doi.org/10.1111/bjh.14107. - PubMed
    1. Delia M, Pastore D, Carluccio P, Pasciolla C, Ricco A, Rossi AR, et al. FLAG-Ida regimen as bridge therapy to allotransplantation in refractory/relapsed acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2017;17(11):767–73. https://doi.org/10.1016/j.clml.2017.06.002. - PubMed
    1. Wang L, Xu J, Tian X, Lv T, Yuan G. Analysis of efficacy and prognostic factors of CLAG treatment in Chinese patients with refractory or relapsed acute myeloid leukemia. Acta Haematol. 2019;141(1):43–53. https://doi.org/10.1159/000493250. - PubMed